On Tuesday, Emergent Biosolutions Inc (NYSE: EBS) opened lower -4.01% from the last session, before settling in for the closing price of $5.73. Price fluctuations for EBS have ranged from $1.82 to $15.10 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 2.20% annually for the last half of the decade. Company’s average yearly earnings per share was noted 598.55% at the time writing. With a float of $52.32 million, this company’s outstanding shares have now reached $54.30 million.
In an organization with 900 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 30.86%, operating margin of -6.19%, and the pretax margin is -13.76%.
Emergent Biosolutions Inc (EBS) Insider Updates
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Emergent Biosolutions Inc is 3.72%, while institutional ownership is 63.92%. The most recent insider transaction that took place on Mar 12 ’25, was worth 204,050. In this transaction Director of this company sold 35,000 shares at a rate of $5.83, taking the stock ownership to the 101,100 shares. Before that another transaction happened on Mar 12 ’25, when Company’s Director sold 10,000 for $5.73, making the entire transaction worth $57,300. This insider now owns 44,482 shares in total.
Emergent Biosolutions Inc (EBS) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 598.55% per share during the next fiscal year.
Emergent Biosolutions Inc (NYSE: EBS) Trading Performance Indicators
Check out the current performance indicators for Emergent Biosolutions Inc (EBS). In the past quarter, the stock posted a quick ratio of 1.77. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.29. Likewise, its price to free cash flow for the trailing twelve months is 8.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.72, a number that is poised to hit 0.49 in the next quarter and is forecasted to reach 0.83 in one year’s time.
Technical Analysis of Emergent Biosolutions Inc (EBS)
Let’s dig in a bit further. During the last 5-days, its volume was 1.01 million. That was inferior than the volume of 1.15 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 24.99%. Additionally, its Average True Range was 0.48.
During the past 100 days, Emergent Biosolutions Inc’s (EBS) raw stochastic average was set at 5.98%, which indicates a significant decrease from 21.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.97% in the past 14 days, which was lower than the 82.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.32, while its 200-day Moving Average is $8.75. However, in the short run, Emergent Biosolutions Inc’s stock first resistance to watch stands at $5.67. Second resistance stands at $5.84. The third major resistance level sits at $5.95. If the price goes on to break the first support level at $5.39, it is likely to go to the next support level at $5.28. Assuming the price breaks the second support level, the third support level stands at $5.11.
Emergent Biosolutions Inc (NYSE: EBS) Key Stats
There are currently 54,337K shares outstanding in the company with a market cap of 298.85 million. Presently, the company’s annual sales total 1,044 M according to its annual income of -190,600 K. Last quarter, the company’s sales amounted to 194,700 K and its income totaled -31,300 K.
